mcrb + 증권 미국 기업 mcrb Investors and News | Seres TherapeuticsThe Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts. wono | discuss | tweet + mcrb seres therapeutics Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome DrugSeres Therapeutics Inc (NASDAQ: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI). The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated. The ECOSPOR III and ECOSPOR IV studies conclude the SER-109 Phase 3 development program. In ECOSPOR IV, subjects treated with SER-109 had a recurrence rate of 8.7% at eight weeks, which indicates a 91.3% sustained clinic wono | discuss | tweet
+ 증권 미국 기업 mcrb Investors and News | Seres TherapeuticsThe Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts. wono | discuss | tweet
+ mcrb seres therapeutics Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome DrugSeres Therapeutics Inc (NASDAQ: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI). The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated. The ECOSPOR III and ECOSPOR IV studies conclude the SER-109 Phase 3 development program. In ECOSPOR IV, subjects treated with SER-109 had a recurrence rate of 8.7% at eight weeks, which indicates a 91.3% sustained clinic wono | discuss | tweet